Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Change in Accured Expenses (2016 - 2025)

Corcept Therapeutics' Change in Accured Expenses history spans 10 years, with the latest figure at $9.5 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 163.19% year-over-year to $9.5 million; the TTM value through Dec 2025 reached $3.9 million, down 68.67%, while the annual FY2025 figure was $3.9 million, 68.67% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was $9.5 million at Corcept Therapeutics, up from -$5.6 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $26.9 million in Q3 2024 and bottomed at -$15.0 million in Q4 2024.
  • The 5-year median for Change in Accured Expenses is $3.4 million (2021), against an average of $2.2 million.
  • The largest YoY upside for Change in Accured Expenses was 1679.93% in 2022 against a maximum downside of 401.45% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at $7.3 million in 2021, then tumbled by 78.23% to $1.6 million in 2022, then surged by 583.17% to $10.9 million in 2023, then crashed by 237.34% to -$15.0 million in 2024, then soared by 163.19% to $9.5 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Change in Accured Expenses are $9.5 million (Q4 2025), -$5.6 million (Q3 2025), and $5.9 million (Q2 2025).